Literature DB >> 2226486

Evaluation of safety and tolerance in clinical trials with antimicrobial agents.

H Lode1, R Stahlmann.   

Abstract

In this review the general and specific difficulties encountered in the evaluation of safety and tolerance of antimicrobial agents in clinical trials are discussed. In addition to the usual pharmacological and toxicological effects (adverse drug reactions) occurring in individual patients, microbiologically induced side-effects also have to be considered. The different methods for registration of side-effects and their limitations are discussed. A system is proposed for evaluation of the cause/effect relationships of adverse drug reactions. A system is also discussed for the evaluation of the severity of adverse drug reactions, and different classifications are presented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2226486     DOI: 10.1007/bf01964297

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  PRE-EXISTING CONDITIONS, PLACEBO REACTIONS, AND "SIDE EFFECTS".

Authors:  D M GREEN
Journal:  Ann Intern Med       Date:  1964-02       Impact factor: 25.391

2.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

3.  Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

4.  Studies of beta-lactam antibiotics in systemic infections: some personal observations over 25 years.

Authors:  A M Geddes
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

Review 5.  Guidelines for evaluating new antimicrobial agents.

Authors:  D N Gilbert
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

6.  Side effects of ofloxacin in clinical trials and in postmarketing surveillance.

Authors:  G Jüngst; R Mohr
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.